France
# |
Name |
Cash and Short-Term Investments |
Reported Date | Stock Price |
Change |
Price (30 days) | Country |
---|---|---|---|---|---|---|---|
1 |
USD 9.61 B
|
Dec. 31, 2023 | USD 107.78 | 1.15% |
|
France |
|
2 |
USD 288.07 M
|
Dec. 31, 2023 | USD 5.91 | -2.66% |
|
France |
|
3 |
USD 162.76 M
|
Dec. 31, 2023 | USD 75.53 | 2.94% |
|
France |
|
4 |
USD 141.37 M
|
Dec. 31, 2023 | USD 4.22 | -0.94% |
|
France |
|
5 |
USD 139.16 M
|
Dec. 31, 2023 | USD 3.21 | 17.34% |
|
France |
|
6 |
USD 102.05 M
|
Dec. 31, 2023 | USD 2.01 | -0.78% |
|
France |
|
7 |
USD 98.26 M
|
Dec. 31, 2023 | USD 26.53 | -0.92% |
|
France |
|
8 |
USD 83.09 M
|
Dec. 31, 2023 | USD 3.47 | -1.52% |
|
France |
|
9 |
USD 56.06 M
|
Dec. 31, 2023 | USD 0.65 | 1.19% |
|
France |
|
10 |
USD 29.79 M
|
Dec. 31, 2023 | USD 2.43 | 0.68% |
|
France |
|
11 |
USD 27.61 M
|
Dec. 31, 2023 | USD 1.39 | 1.77% |
|
France |
|
12 |
USD 22.33 M
|
Dec. 31, 2023 | USD 2.58 | -11.21% |
|
France |
|
13 |
USD 21.00 M
|
March 31, 2024 | USD 16.83 | 1.50% |
|
France |
|
14 |
USD 20.61 M
|
Dec. 31, 2023 | USD 6.63 | -0.22% |
|
France |
|
15 |
USD 14.31 M
|
Dec. 31, 2023 | USD 5.64 | -2.27% |
|
France |
|
16 |
USD 6.70 M
|
Dec. 31, 2023 | USD 1.64 | 4.90% |
|
France |
|
17 |
USD 4.70 M
|
Dec. 31, 2023 | USD 3.53 | -0.92% |
|
France |
The Vaccines company in France with the highest Cash and Short-Term Investments is Sanofi (Paris Stock Exchange: SAN.PA) at USD 9.61 B.
The Vaccines company in France with the lowest Cash and Short-Term Investments is genOway SA (Paris Stock Exchange: ALGEN.PA) at USD 4.70 M.
The top 10 Vaccines companies in France by Cash and Short-Term Investments are Sanofi, ABIVAX SA, Vetoquinol SA, DBV Technologies S.A., Valneva SE, Innate Pharma S.A., Eurobio Scientific SA, Nanobiotix S.A., Novacyt S.A. and Inventiva S.A..
The bottom 10 Vaccines companies in France by Cash and Short-Term Investments are genOway SA, AB Science S.A., Adocia SA, OSE Immunotherapeutics SA, MedinCell S.A., Aelis Farma SA, Valbiotis SA, Inventiva S.A., Novacyt S.A. and Nanobiotix S.A..